Novo Nordisk’s Ozempic gains USFDA approves to cut risk of diabetic kidney disease progression Reuters Jan 29, 2025 The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney…
Race for approval of first oral GLP-1R drug in obesity intensifies with four in phase III trials:… EP News Bureau Dec 2, 2024 Oral GLP-1 receptor drugs emerge as the next frontier in obesity treatment, with key players racing for first approval amidst…
